Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

Recruiting now · Phase 2

Conditions studied: Cell Carcinoma

In brief

his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp

Key facts

Study ID

NCT06112522

Run by

Centre Hospitalier Universitaire de Nice

People needed

50

Starts

2024-02-16

Expected to finish

2027-12-16

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Histologically confirmed,
• primary, previously untreated,
• superficial basal cell carcinoma (sBCC) not arising on the face or scalp, ≤ 15 mm (large axis)

You may not qualify if…

• BCC of the face or scalp
• BCC of non-superficial subtype
• BCC with large axis > 15mm
• Relapsing BCC
• Allergy to treatment
• Treatment with cryotherapy, imiquimod, PDT, or radiotherapy in the BCC area during the 6 months prior to the screening visit

Where it is running

• CHU de Nice - Hôpital de l'Archet — Nice, Alpes-maritimes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.